French microbiologist Emmanuelle Charpentier, who discovered a revolutionary and controversial gene editing technique called Crispr-Cas9, has been striking lucrative licensing deals with the likes of Bayer and Japanese pharma giant Daiichi Sankyo through her Irish company ERS Genomics.
Charpentier, along with biochemist Jennifer Doudna, developed Crispr-Cas9 in 2013 with researchers from the University of Berkeley California and the University of Vienna.
The technique allows scientists to more precisely target the genes that control certain traits, as...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team